Thursday 7 May, 2026
Introduction: Busulfan is a cornerstone of conditioning regimens prior to hematopoietic stem cell transplantation (HCT). It has a narrow therapeutic…
Read morePoster: Clinical Applications
Structured fit-for-purpose evaluation of model-informed precision dosing of mycophenolic acid and tacrolimus in pediatric patients with renal disease
Thursday 7 May, 2026
Objectives Mycophenolic acid (MPA) and tacrolimus are frequently used in kidney diseases like kidney transplantation and nephrotic syndrome. The use…
Read moreSex differences in sunitinib tolerability and patient-reported outcomes in metastatic renal cell carcinoma: the role of exposure and implications for precision dosing
Thursday 7 May, 2026
Objectives Biological sex contributes to variability in sunitinib pharmacokinetics, but the implications for tolerability, treatment modifications, and patient-reported side-effect burden…
Read moreIndividualized Vancomycin Dosing Using Bayesian Modeling in Pediatric Patients with Lymphomas and Leukemias
Thursday 7 May, 2026
Introduction Clinicians are increasingly faced with a wide array of pharmacokinetic (PK) models developed for various patient populations. Selecting the…
Read morePOPULATION PHARMACOKINETICS AND EXPOSURE–RESPONSE MODELING SUPPORTS OPTIMIZED USTEKINUMAB INDUCTION DOSING IN CHRONIC POUCHITIS
Thursday 7 May, 2026
Introduction: Pouchitis is a frequent and clinically significant complication following restorative proctocolectomy with ileal pouch–anal anastomosis in patients with ulcerative…
Read morePopulation Pharmacokinetics/Pharmacodynamics (PK/PD) and Time-to-Event (TTE) Analysis of Major Bleeding for Rivaroxaban-Treated Patients with Atrial Fibrillation: Assessing the Influence of Heart Failure through Left- and Right-Ventricular Performance Markers
Thursday 7 May, 2026
OBJECTIVES: Rivaroxaban is a cornerstone of stroke prevention in atrial fibrillation (AF), yet major bleeding remains a significant clinical concern…
Read moreA PK/PD WORKFLOW TO SUPPORT THE SELECTION OF EMPIRICAL ANTIBIOTIC COMBINATIONS: APPLICATION TO NEONATAL SEPSIS IN LOW- AND MIDDLE-INCOME COUNTRIES
Thursday 7 May, 2026
Introduction Neonatal sepsis remains a major global health challenge, with the highest incidence and mortality occurring in low- and middle-income…
Read moreAssessing Vancomycin PK Model Performance Across Trough- and AUC-Based Targets in Diverse Patient Populations
Thursday 7 May, 2026
Introduction: Vancomycin remains one of the most extensively studied drugs in population pharmacokinetic (popPK) modeling, with a large number of…
Read morePharmacometric evaluation of extended interval dosing of IV-administered nivolumab using an established popPK model and sparse trough sampling: REFINE Nivolumab Cohort Interim Pharmacokinetic Analysis
Thursday 7 May, 2026
Introduction: Nivolumab, an immune checkpoint inhibitor (ICI) targeting programmed cell death protein 1 (PD-1), is an ideal candidate for reduced…
Read moreImpact of PK/PD indices on target attainment of vancomycin therapy in critically ill children: back to the drawing board
Thursday 7 May, 2026
Introduction Vancomycin is a moderately plasma protein-bound glycopeptide antibiotic used to treat severe infections caused by Gram-positive bacteria [1]. Sub-…
Read more